-
Halperin's study, called Sportif V, followed 3, 922 patients who were randomly given either warfarin or Exanta.
FORBES: Magazine Article
-
Uncertainties about DECREASE IV, DECREASE V-pilot study, and pilot studies for DECREASE VI are soon to be communicated to the respective journals so that further action may be taken.
FORBES: Embers Of Poldermans Case Still Smoldering
-
Merck announced today that the HPS2-THRIVE ( H eart P rotection S tudy 2- T reatment of H DL to R educe the I ncidence of V ascular E vents) study did not meet its primary endpoint.
FORBES: HPS2-THRIVE: No Benefit, Signal Of Harm For Niacin Therapy
-
Three of the authors of the study, General John Foss (USA, Ret..), Eugene V.
CENTERFORSECURITYPOLICY: A US force for the Golan Heights? A roundtable discussion
-
Chief executive Kundapur Vaman (K.V.) Kamath, an avid fan of Formula One racing, presented a case study of a thrilling Grand Prix in Brazil in October.
FORBES: Risk and Reward